LIVE
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

BHEL’s Record Nigeria Order & Gland Pharma’s USFDA Approval

By ThePip DeskBHEL’s Record Nigeria Order & Gland Pharma’s USFDA Approval

BHEL secures its largest Nigeria order for Gas Turbine Generators. Gland Pharma receives USFDA approval for Sugammadex Injection. Key business and market updates.

Bharat Heavy Electricals (BHEL) has secured its largest-ever single order, involving eight Gas Turbine Generator packages, from Dangote Petroleum Refinery and Petrochemicals Free Zone Enterprise in Nigeria. This significant contract underscores BHEL’s expanding global presence in heavy electrical manufacturing.

The substantial BHEL contract encompasses the manufacture and supply of these critical packages, along with the supervision of erection and commissioning activities at the Nigerian site. This comprehensive scope highlights the company’s end-to-end capabilities in large-scale industrial projects.

BHEL’s Record-Breaking Order Details

  • Order Type: Supply & Supervision basis for eight Gas Turbine Generator packages.
  • Client: Dangote Petroleum Refinery and Petrochemicals Free Zone Enterprise, Nigeria, part of the Dangote Group.
  • Manufacturing Locations: BHEL’s facilities in Hyderabad and Bengaluru.

Gland Pharma’s USFDA approval pertains to its Abbreviated New Drug Application for Sugammadex Injection, available in two single-dose vial strengths. This approval allows Gland Pharma to market a product bioequivalent to a significant market leader.

Gland Pharma Secures USFDA Nod

  • Approved Product: Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials.
  • Bioequivalence: Therapeutically equivalent to BRIDION Injection by Merck Sharp & Dohme LLC.
  • Indication: Reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
  • Market Data (IQVIA): The product recorded US sales of approximately $1.6 billion for the twelve months ending April 2026.

These dual developments mark significant milestones for both Indian companies, with BHEL solidifying its international footprint through its largest contract to date, and Gland Pharma entering a substantial segment of the US pharmaceutical market with a key product. Both announcements reflect positive movements for their respective sectors.

Home/business/Article